TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18435378

Group type: EXPERIMENTAL
Intervention: Flowable composites (Gradia LoFlo; Filtek Supreme XT Flow)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesives (Adper Scotchbond 1XT, Scotchbond Multi‐Purpose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intermediate agent applied)
Number of subjects: 30
Study: 16598527

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in high-risk patients with AF
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (patients with AF without echocardiographic risk factors)
Number of subjects: 128
Study: 12560311

Group type: EXPERIMENTAL
Intervention: Morbid obesity (SG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-obese (CG)
Number of subjects: 200
Study: 10837379

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 224

Group type: COMPARATOR
Intervention: Dorzolamide 2% three times daily
Number of subjects: 224
Study: 9397397

Group type: EXPERIMENTAL
Intervention: High-DHA diet (6 g/d of DHA in the form of a triglyceride containing 40% DHA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-DHA diet (< 50 mg/d of DHA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-DHA diet
Number of subjects: 10
Study: 8475977

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 40
Study: 3812046

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Focussed smoking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Attention placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 60
Study: 29684832

Group type: EXPERIMENTAL
Intervention: Sucrose (0.2 ml/kg of 20%) plus non-nutritive sucking group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sucrose (0.2 ml/kg of 20%) group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 86
Study: 27084093

Group type: EXPERIMENTAL
Intervention: Nordic school meals rich in fish, vegetables, and potatoes
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Potato intake
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Whole-grain, dietary fiber, protein, and fat intakes
Number of subjects: 523
Study: 24635006

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation individualized activity intervention
Number of subjects: 71
Study: 22453568

Group type: EXPERIMENTAL
Intervention: Imatinib 36 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Imatinib 12 months
Number of subjects: 200
Study: 20569786

Group type: EXPERIMENTAL
Intervention: Primary Care PCIT (PC‐PCIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PCIT Anticipatory Guidance (PCIT‐AG)
Number of subjects: 30
Study: 17042738

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 microg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Alendronate (ALN) 10 mg/day
Number of subjects: 53
Study: 14730238

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Itraconazole (400 mg)
Number of subjects: 40
Study: 11701727

Group type: EXPERIMENTAL
Intervention: Improved glycemic control (IC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual glycemic control (UC)
Number of subjects: 43
Study: 9308742

Group type: EXPERIMENTAL
Intervention: Short prophylaxis with low molecular weight heparin (LMWH) during hospitalisation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Prolonged prophylaxis with low molecular weight heparin (LMWH) for three weeks after hospitalisation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Short prophylaxis with low molecular weight heparin (LMWH)
Number of subjects: 198
Study: 7701033

Group type: EXPERIMENTAL
Intervention: Naltrexone, 25 mg orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 11
Study: 3661052

Group type: EXPERIMENTAL
Intervention: Aldosterone (1.0 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluocortolone (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (80 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31689641

Group type: EXPERIMENTAL
Intervention: BMI-MTM
Number of subjects: 32

Group type: COMPARATOR
Intervention: SMC
Number of subjects: 32
Study: 28731780

Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip (CHX) in addition to scaling and root planing (SRP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Turmeric chip in addition to scaling and root planing (SRP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 120
Study: 26413749

Group type: EXPERIMENTAL
Intervention: 25 mg daily oral spironolactone for 12 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Matching placebo for 12 weeks
Number of subjects: 86
Study: 23444322

Group type: EXPERIMENTAL
Intervention: Computer-based administration of the STOFHLA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paper-based administration of the STOFHLA
Number of subjects: 80
Study: 22335183

Group type: EXPERIMENTAL
Intervention: Naltrexone with medical management
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Brief counseling intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination of naltrexone and brief counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (standard tuberculosis treatment without alcohol intervention)
Number of subjects: 200
Study: 19726350

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with isoflurane (1%-2%) and sodium nitroprusside (0.3-3 microg.kg(-1).min(-1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with isoflurane (1%-2%) and glonoin (0.5-5 microg.kg(-1).min(-1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine general anesthesia (group A)
Number of subjects: 30
Study: 17474559

Group type: EXPERIMENTAL
Intervention: predilution hemodiafiltration (HDF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: low-flux hemodialysis (HD)
Number of subjects: 13
Study: 15911473

Group type: EXPERIMENTAL
Intervention: Saw palmetto (study medication)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1
Study: 12038493

Group type: EXPERIMENTAL
Intervention: Common lures containing constituents from bizarre target items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bizarre lures containing constituents from common target items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased verbal elaboration
Number of subjects: 0
Study: 10367023

Group type: EXPERIMENTAL
Intervention: Exercise training programs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strength training programs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 25
Study: 7564452

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 30
Study: 2202239

Group type: EXPERIMENTAL
Intervention: Experimental drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7018165

Group type: EXPERIMENTAL
Intervention: Natural estrogen (estradiol‐17 beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg per tablet)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Artificial estrogen (ethinyl estradiol 50 micrograms/ norethisterone acetate 3 mg per tablet)
Number of subjects: 111
Study: 31438790

Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Release surgery with Dexamethasone injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Carpal Tunnel Release surgery alone
Number of subjects: 65
Study: 28656463

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI) parameters including signal fat fraction (sFF) and apparent diffusion coefficient (ADC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI) parameters
Number of subjects: 21
Study: 25574939

Group type: EXPERIMENTAL
Intervention: Access to social support sections plus gaming
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Access to social support features
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Access to both social support features and gaming
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Access to social support sections
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Access to gaming experience
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Gamified experience
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no access to the website)
Number of subjects: 157
Study: 23652893

Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream (Promiseb® Topical Cream); applied topically twice daily for up to 14 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo cream; applied topically twice daily for up to 14 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nonsteroidal cream
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study: 21856230

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg)
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Daily recombinant FSH (rFSH) (200 IU)
Number of subjects: 1506
Study: 19565745

Group type: EXPERIMENTAL
Intervention: Bee-needle therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine acupuncture with fire-cupping or warm needle moxibustion
Number of subjects: 150
Study: 17448376

Group type: EXPERIMENTAL
Intervention: BNP-guided therapy (goal of decreasing BNP plasma levels <100 pg/ml)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Clinical group (medical treatment according to current guidelines)
Number of subjects: 220
Study: 15334509

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI); 28 days of twice-daily inhalation followed by 28 days off for 56 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Routine subject management (control group)
Number of subjects: 184
Study: 11568032

Group type: EXPERIMENTAL
Intervention: Chronic calcium channel blocker therapy (CCCBT) continued with diltiazem (120 mg/d) for 5 years
Number of subjects: 120

Group type: COMPARATOR
Intervention: Suspension of chronic calcium channel blocker therapy (CCCBT)
Number of subjects: 120
Study: 9613738

Group type: EXPERIMENTAL
Intervention: Gabapentin (1800 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8086868

Group type: EXPERIMENTAL
Intervention: Preterm formula
Number of subjects: 758

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 758

Group type: COMPARATOR
Intervention: Donor breast milk
Number of subjects: 758

Group type: COMPARATOR
Intervention: Mother's milk
Number of subjects: 758
Study: 2199619

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (60 weeks)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 646
Study: 686545

Group type: EXPERIMENTAL
Intervention: Reinforced disulfiram treatment (methadone contingent upon disulfiram ingestion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients urged to take disulfiram but received methadone regardless)
Number of subjects: 0
Study: 30640250

Group type: EXPERIMENTAL
Intervention: Epi-Bowman blunt keratectomy (EBK)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diluted ethanol (EtOH)
Number of subjects: 22
Study: 27686569

Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery (tension-free vaginal tape)
Number of subjects: 176
Study: 25526229

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22509011

Group type: EXPERIMENTAL
Intervention: Western culture individuals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eastern culture individuals
Number of subjects: 30
Study: 21197512

Group type: COMPARATOR
Intervention: HS + LA (2% lidocaine in 0.2 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: HS + ketorolac (3 mg in 0.2 mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: HS alone (control)
Number of subjects: 12
Study: 18295556

Group type: EXPERIMENTAL
Intervention: Clopidogrel preparation 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clopidogrel preparation 2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Method validation
Number of subjects: 24
Study: 15761294

Group type: EXPERIMENTAL
Intervention: Occupational exposure to x rays
Number of subjects: 0
Study: 14512675

Group type: EXPERIMENTAL
Intervention: LIFE system (Xillix Technologies)
Number of subjects: 332

Group type: COMPARATOR
Intervention: D-light system (Storz)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: LIFE system
Number of subjects: 332

Group type: COMPARATOR
Intervention: D-light system
Number of subjects: 332
Study: 10389780

Group type: EXPERIMENTAL
Intervention: TEE-guided CVC placement
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (non-TEE guided)
Number of subjects: 145
Study: 8778554

Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus Maxim L (ESML)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 1667345

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (LAVV)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 46
Study: 6360936

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg daily (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg daily (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 50
Study: 31813866

Group type: EXPERIMENTAL
Intervention: 1% aspirin gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% aspirin mouthwash
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study: 29523415

Group type: EXPERIMENTAL
Intervention: Mifepristone (1200 mg/day)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Mifepristone (high plasma level group ≥1637 ng/mL)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Mifepristone (low plasma level group)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study: 26672686

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT screening strategy
Number of subjects: 399

Group type: COMPARATOR
Intervention: Limited screening strategy
Number of subjects: 399
Study: 24163120

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg once daily for 6 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atorvastatin (40 mg once daily for 6 weeks)
Number of subjects: 83
Study: 22810568

Group type: EXPERIMENTAL
Intervention: Zhemchuzhnaya‐complex protection toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noviy zhemchug ftor toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zhemchug svezhaya myata toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20606658

Group type: EXPERIMENTAL
Intervention: venlafaxine 75 mg q.h.s. for 4 weeks
Number of subjects: 43
Study: 17416907

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg‐1
Number of subjects: 68

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg kg‐1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg‐1
Number of subjects: 68
Study: 16784365

Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 15276659

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 37.5 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150 mg
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 544
Study: 10720128

Group type: EXPERIMENTAL
Intervention: Cranial Radiation Therapy (CRT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: No Cranial Radiation Therapy (CRT-)
Number of subjects: 222
Study: 8965154

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (2 liters of a nutritive amino acid solution containing approximately 2.25 g/liter lysine‐glutamate and 2.50 g/liter arginine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 80
Study: 1389189

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg of nitroglycerin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms/kg of nitroglycerin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 4008387

Group type: EXPERIMENTAL
Intervention: Piperacillin + Gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin + Gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mezlocillin + Gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticarcillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study: 31280997

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (200 mg/kg per hour for the first 8 hours, followed by 100 mg/kg per hour for another 16 hours, same dose for another 24 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no N-acetylcysteine)
Number of subjects: 30
Study: 30942658

Group type: EXPERIMENTAL
Intervention: Practice Target group (received individual AQM data compared to target AQM goals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer Comparison group (received information on individual AQM data compared to average performance of residents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received an email with contact information of a population health coordinator and a list of AQMs)
Number of subjects: 0
Study: 28745035

Group type: EXPERIMENTAL
Intervention: Non-resorbable d‐PTFE titanium‐reinforced membranes (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium meshes covered by cross‐linked collagen membranes (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study: 26466684

Group type: EXPERIMENTAL
Intervention: First-line antidepressant minimum dosing strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-line antidepressant maximum dosing strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line antidepressant continuation strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line antidepressant augmentation strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line antidepressant switching strategy
Number of subjects: 0
Study: 23387504

Group type: EXPERIMENTAL
Intervention: 9-week yoga intervention
Number of subjects: 51
Study: 21411151

Group type: EXPERIMENTAL
Intervention: 5 mL chlorhexidine (CHX) application
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (no swab)
Number of subjects: 145
Study: 19644062

Group type: EXPERIMENTAL
Intervention: TRPM7 gene variation (16 tag-SNPs)
Number of subjects: 490
Study: 17700131

Group type: EXPERIMENTAL
Intervention: Contour I device treatment (one treatment in abdomen, thighs, or flanks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Safety monitoring (laboratory testing, pulse oximetry, liver ultrasound)
Number of subjects: 164
Study: 15499438

Group type: COMPARATOR
Intervention: WHO-17D and Brazilian 17DD yellow fever vaccines
Number of subjects: 1087
Study: 11509308

Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation service
Number of subjects: 140

Group type: COMPARATOR
Intervention: Geriatric day-hospital care
Number of subjects: 140
Study: 9747404

Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 74
Study: 7882701

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 81
Study: 3586503

Group type: COMPARATOR
Intervention: Intravenous deferoxamine (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous deferoxamine (1 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular deferoxamine (1 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal deferoxamine (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous and intraperitoneal deferoxamine
Number of subjects: 0
Study: 30992071

Group type: EXPERIMENTAL
Intervention: Uro-Vaxom®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28034064

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Three-Dimensional Conformal External Beam Radiation Therapy (3D-CRT)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D-CRT
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 482

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 482
Study: 26579041

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBTp)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 358
Study: 23761037

Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/d) plus lithium
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/d) plus divalproex
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo plus lithium
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo plus divalproex
Number of subjects: 1326
Study: 21615934

Group type: EXPERIMENTAL
Intervention: Brief intervention based on the Information-Motivation-Behavioural Skills (IMB) Model
Number of subjects: 520

Group type: COMPARATOR
Intervention: Alcohol use health education leaflet
Number of subjects: 520